Bruce Power is expanding its medical research and development opportunities.
The company has signed an agreement with a specialized radiopharmaceuticals company to explore the production of the medical radioisotope Lutetium-177.
Medical-grade Lutetium is used to destroy cancer cells while leaving healthy cells unaffected. It's most often used to treat neuroendocrine tumours and prostate cancer.
The companies have signed a Memorandum of Understanding to explore the production of Lutetium-177 at Bruce Power's CANDU reactors.
Development, processing, and global distribution of Lutetium-177 will be managed by ITG, a subsidiary of German-based Isotopen Technologien München (ITM).
"We are looking forward to working with Bruce Power to secure a new global supply source of our medical-grade Lutetium," said Steffen Schuster, CEO of ITM. "With Bruce Power’s long-term outlook to operate its facility through 2064 and its existing expertise with Cobalt production, we have the opportunity to provide a stable source of Lutetium177 to cancer patients worldwide."
